CDTI (CDTI) Stock Price & Analysis
CDTI (CDTI) rose 0.00% to USD 0.74 as of July 25, 2026 at 14:25 UTC, according to Nexqual real-time market data.
CDTI last closed at USD 0.74; the session ranged USD 0.9–0.9 on volume of 100 shares. Market capitalization is $3.33M, with a 52-week range of USD 0.43–1.99 (PNK). Source: Nexqual, July 25, 2026 at 14:25 UTC.
Key Statistics (as of July 25, 2026 at 14:25 UTC)
| Price | USD 0.74 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.74 |
| Open | USD 0.9 |
| Day Range | USD 0.9 – 0.9 |
| 52-Week Range | USD 0.43 – 1.99 |
| Volume | 100 shares |
| Market Cap | $3.33M |
| Exchange | PNK |
Technical Analysis (CDTI)
Nexqual's technical model rates CDTI "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 14:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 46.93 (neutral) |
| vs SMA50 | Below (USD 0.75) |
| MACD | 0 (positive) |
Analyst Ratings (CDTI)
Wall Street analysts rate CDTI "None", per Nexqual as of July 25, 2026 at 14:25 UTC.
| Consensus Rating | None |
|---|
Earnings (CDTI)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2018-06-30 | USD -0.52 vs est -0.45 ▼ miss |
| 2018-03-31 | USD -0.21 vs est -0.4 ▲ beat |
| 2017-12-31 | USD -0.52 vs est -0.35 ▼ miss |
| 2017-09-30 | USD -0.23 vs est -0.3 ▲ beat |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Financials & Fundamentals (CDTI)
| Total Revenue | $9.95M |
|---|---|
| Revenue Growth (YoY) | -34.80% |
| Gross Margin | +39.12% |
| Operating Margin | -14.70% |
| Profit Margin | +0.81% |
| ROE | +2.56% |
| Current Ratio | 2.3 |
| Total Cash | $1.81M |
| Total Debt | $0 |
| Free Cash Flow | $-724,500 |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Financial Health Score (CDTI)
Nexqual rates CDTI's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 14:25 UTC.
| Growth | Critical — Revenue -23% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $2M cash, no debt |
| Cash Flow | Weak — FCF negative: -$725K, burning cash |
| Efficiency | Weak — ROE 3%, ROA 1.4% |
Ownership (CDTI)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.50M |
| Short % of Float | +12.02% |
Source: Nexqual, July 25, 2026 at 14:25 UTC.
Leadership (CDTI)
CDTI is led by Matthew Beale (age 58), President, CEO & Director, per Nexqual as of July 25, 2026 at 14:25 UTC.
| President, CEO & Director | Matthew Beale (age 58) |
|---|---|
| CFO & Corporate Secretary | Tracy A. Kern (age 57) |
| Vice President of Operations | Albert De Loa |
| Chief Technology Officer | Edward J. Lee |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BSPM | Biostar Pharmaceuticals, Inc. | USD 0 | ▲ 0% |
| LIVE | Live Ventures Incorporated | USD 9.69 | ▼ 8.15% |
| ICLD | INTERCLOUD SYSTEMS INC | USD 0 | ▲ 0% |
| ANTH | ANTHERA PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| CREG | Smart Powerr Corp. | USD 0.77 | ▲ 354.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 14:25 UTC. This page is informational and not investment advice.